HIG Capital has completed the sale of clinical research organisation Celerion Holdings to funds affiliated with THL Partners in a $1.8bn transaction, marking another realisation from its Advantage investment strategy amid an improving backdrop for private equity exits.
Celerion, which provides early-stage clinical trial and drug development services to pharmaceutical and biotech companies, represents a core healthcare services asset within HIG’s portfolio. The business operates across North America, Europe and Asia, supporting drug development from first-in-human studies through to proof-of-concept trials.
The transaction is the latest in a series of disposals under HIG’s Advantage strategy, which has recently completed multiple exits including St. Croix and United Flow Technologies. Together, these sales represent more than $4.5bn in combined enterprise value since late 2025, reflecting a sustained push to monetise mature portfolio companies.
HIG highlighted its operational value-creation approach, noting that the strategy focuses on building scale in established mid-market businesses through active management and targeted transformation initiatives. The firm, which manages approximately $75bn in assets, invests across buyouts, credit, real estate and infrastructure strategies globally.
The Celerion exit comes at a time when private equity firms are increasingly seeking to accelerate distributions to investors following a period of slower dealmaking and constrained exit channels. Improved sentiment in parts of the M&A market has contributed to a modest recovery in realisation activity, particularly for high-quality assets in resilient sectors such as healthcare services.
Overall, the deal underscores a broader trend of selective but strengthening exit momentum in private equity, as managers look to return capital and demonstrate performance despite a still uneven transaction environment.
